Placebos have been used extensively by vast numbers of physicians, in a majority of clinical trials. Placebo effects involve behavioural, psychological and genetic factors and have been subject to ethical controversies stemming from the use of deception in treating patients. The patient-physician encounter, endogenous pharmacological pathways, personality traits and genetic diversity have all been reported to be key players in placebo responses. In the last decade, a new methodological paradigm of placebo research has emerged, using open-label placebos to investigate their effects which showed promising results for various common medical conditions. In this review, we will summarize the current body of evidence on placebos in clinical practice, with a view to open-label placebo trials in particular. It is our view that future larger-scale randomized blinded open placebo trials will benefit physicians and improve patient outcomes.
| INTRODUCTION
Placebos have been reported to be effective in multiple medical conditions for more than half a century. In the previous decade, the general attitude among clinicians and the understanding of the mechanisms of placebo effects have changed dramatically. The term "placebo" entered medical vocabulary in the late 18th century indirectly by way of Latin translations of the Bible, notably Psalm 116 which was sung in the Vespers for the Dead, a Catholic rite no longer prevalent. 1, 2 The word entered English usage in the 13th century, retaining the meaning "to please," and appears in two stories of Chaucer's Canterbury Tales (1387). 2, 3 In the 19th century, placebo agents such as pills and injections were widely used in clinical practice but were associated mainly with providing comfort rather than producing appreciable therapeutic benefit. 4 By the turn of the 20th century, however, physicians began to examine the contents, as well as the contexts, of placebo treatments more critically. The term "placebo effect" appeared in the context of controlled clinical trials shortly after World War II, in a milieu of strident concern for moral and ethical principles in clinical research, following publication of the Nuremburg Code. [5] [6] [7] In the 1950s, conflicting opinions surfaced in the medical community with regard to placebo treatments. Some cited their widespread use in the United States and Europe, while others were more disparaging, looking down on patient naiveté.
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| PSYCHOSOCIAL DETERMINANTS OF PLACEBO EFFECTS
| The therapeutic encounter
The doctor-patient relationship has great influence on certain placebo effects and can even affect the natural course of disease. 9, 10 Placebo effects, it is important to note, have been found to be separable into different components, and some of the most robust are thought to be dependent on factors surrounding the patient-practitioner relationship. In patients with irritable bowel syndrome, for example, statistically and clinically significant effects on symptoms and quality of life were observed by augmenting the therapeutic encounter with warmth, attention and confidence. 11 In patients with gastroesophageal reflux disease, expanded patient-provider visits-with added consultations in a style of complementary and integrative medicine-provided significant improvements in symptom severity compared to standard empathic visits. 12 In both health and disease, experimental studies strongly suggest the possibility of manipulating therapeutic encounters for the benefit of the patient. 13, 14 These findings together suggest that the nonspecific benefits traditionally ascribed to the placebo effect can be augmented intentionally by careful attention to therapeutic contexts.
| Internal and external context
The seemingly paradoxical physiologic effects of treatment with inert agents can be significantly modulated by real psychosocial and cognitive factors. When treatments are being administered, even subtle contextual cues have been shown to elicit placebo responses. 15 For pain and other nervous system conditions in particular, when patients are unaware that treatment is being given, the treatment is less effective than when given overtly. 16 In fact, much of our understanding of the interplay between psychological and physical factors of placebo effects comes from comparing overt and covert administration of analgesic medications and their antagonists. [15] [16] [17] [18] There is evidence that specific physiologic systems can augment or diminish placebo responses. For example, with endogenous opioid system activation by buprenorphine, or administration of other anti-inflammatory drugs, both psychological and pharmacological factors were found to reduce the effectiveness of the analgesia. 19 Interestingly, placebo responses involving conscious awareness (eg, pain and motor function) have been shown to be mediated by expectation, while those involving unconscious (eg, hormonal) physiological functions are more like conditioned responses. 18 This distinction is important to note, because placebo effects must be distinguished from other physiologic reactions, though these are often juxtaposed clinically. A notable example is that of induced placebo respiratory depression, which was found to be caused by a mechanism more akin to classical (Pavlovian) conditioning, rather than cognitive or motivational factors. 20 Yet, another study found that conditioning treatment cues with positive outcomes led to placebo analgesia even when subjects were aware that a placebo was administered. This study suggests that placebo effects can be present independent of reported expectations for pain relief. 21 Nonetheless, awareness of the psychosocial contexts involved in various treatment modalities is a key for harnessing placebo effects in medicine.
| Patient characteristics
According to a large body of evidence, almost every patient is predisposed to experience placebo responses. It was once thought that certain patients, dubbed "placebo reactors" or "responders," might be experiencing significantly more placebo response than others. 22 , 23 The existence of placebo responders in certain patient populations, though controversial, has been attributed to a variety of social, cultural, biological and genetic factors. [24] [25] [26] [27] Specific personality traits have been found to influence the variance in experimental placebo-induced activation of μ-opioid neurotransmission, for example, neuroticism being a negative predictor of placebo analgesia. 26 Interindividual variations in pain responses have also been linked to a single-nucleotide polymorphism in the μ-opioid receptor gene (OPRM1) A118G. 27 Accordingly, certain genes thought to play a role in cognitive and emotional functions may modulate therapeutic expectations. These polymorphisms correlated with the placebo response are part of a growing body of research concerned with genomic effects on placebo responses, dubbed the "placebome".
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| Population characteristics
Differences in placebo responses in the context of particular illnesses have been examined critically, with a view to reliability of these responses across patient populations. 24 In fact, placebo responses have been shown to rise over time in certain populations. Overall placebo response was shown to have risen significantly from 1960 to 2012 across randomized controlled trials for antipsychotic medications. 31 Understandably, careful selection of patients for placebo-controlled studies has been emphasized, to control for stability of illness, patient characteristics and confounding comorbidities. [32] [33] [34] However, this does not imply placebo groups should be ignored methodologically or excluded from clinical trials. To the contrary, a large meta-analysis of placebo groups in trials of antidepressant medications for major depressive disorder found that placebo responses change over time in these patients, and for this reason, inclusion of placebo groups was deemed to be of major scientific importance. 35 Furthermore, meta-analyses of trials of psychiatric medication have highlighted the need for transparency in disclosing dropouts when placebo responses are suspected. 36 Indeed, placebo responses have been found to play significant roles in a variety therapeutic contexts, from dermatological conditions to surgery. 37, 38 Although theories and models exist for placebo effects and interactions with drug efficacy, responses cannot yet be reliably predicted. The influence of placebo administration on pain is understood to be mediated by a combination of opioid and nonopioid mechanisms (eg, endorphins, cannabinoids and dopamine). 40 First, there is the general concept that placebo treatment may cause the release of endogenous opioids. The endogenous opioid system was first found to play a role in placebo analgesia by studies which demonstrated the potential of naloxone, an opioid antagonist, to diminish placebo responses. 15, [41] [42] [43] Significant increases in CSF β-endorphin measurement following placebo analgesia in chronic pain patients have also been reported. 44 In addition to opioid involvement, potential nonopioid mechanisms have also been identified for placebo analgesia. 17, 45 While naloxone partially abolished placebo analgesia, it was found that proglumide, a cholecystokinin antagonist, enhanced it. [46] [47] [48] More recently, molecular neuroimaging has shown that both high-level, and subcortical μ-opioid receptor-rich regions are active during placebo conditions. 49, 50 Numerous
PET and fMRI studies have described the neural networks thought to represent the central mechanisms of placebo analgesia. [51] [52] [53] [54] These areas include, but are not limited to, the prefrontal cortex, insular cortex, nucleus accumbens, amygdala, periaqueductal grey and dorsal raphe nucleus. In one study, naloxone was suggested to block the communication of pain signals between cortical and subcortical structures. 54 This interaction between the brain's cortical and subcortical pain control systems is thought to be a key aspect of such "opioidergic" phenomena. With advances in neuroimaging, it may be possible to discover which brain signatures are pain-specific, and which arise from purely affective processes. To date, in patients with irritable bowel syndrome, fMRI studies showed large reductions in brain activity for pain-related areas during placebo intervention.
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Recent studies also provide clues about the nonopioid components involved in placebo analgesia, such as the dopaminergic and endocannabinoid systems.
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| Nonanalgesic placebo responses
Nonanalgesic placebo responses are also known, and these depend highly on the specific condition and therapeutic context of treatment. For nervous system disease in particular, for example, in Parkinson Disease (PD), it has been emphasized that patient awareness and expectations are key aspects of achieving optimum therapeutic response. 16 In response to placebo drug administration, PD patients showed endogenous dopamine uptake in the striatum, measured by PET uptake of radio-labelled raclopride. 58 PD patients also showed similar endogenous dopaminergic transmission during placebo (ie, sham) repetitive transcranial magnetic stimulation. 59 Dopaminergic placebo effects in PD were found to be closely linked to patient expectations of clinical improvement, underscoring the need for careful attention to therapeutic context when treating PD patients, especially in the context of transcranial magnetic stimulation or deep brain stimulation.
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Attention has also been paid to endocrine and immune placebo responses, which seem to be mediated by mechanisms more akin to classical (Pavlovian) conditioning. Experimental studies in healthy subjects suggest that measurable changes in growth hormone, cortisol, insulin and immune function markers can be appreciated along with placebo administration. 18, [62] [63] [64] Conditioning also affected immune function in a sample of patients with multiple sclerosis. 65 Interestingly, unlike for pain and motor performance, these "unconscious" secretions seem to be unaffected by verbal suggestion. This observation again highlights the importance of practitioner awareness in the context of placebo treatments. For respiratory function in asthmatic patients, albuterol showed significant objective improvement in forced expiratory volume, while albuterol inhaler, placebo inhaler and sham acupuncture all produced significant subjective improvement. 66 In other words, a significant number of patients reported similar degree of improvement of symptoms from both active drug and placebo.
| Placebo surgeries & procedures
Placebo effects in the context of surgery have been welldocumented. Sham procedures have been used to evaluate placebo effects in the context of interventional cardiology, orthopaedic surgery and neurosurgery. Many aspects of the surgical process besides the incision are thought to contribute to patient outcomes, and evaluating these extra factors may have important safety and financial implications. 5, 67 While placebo-controlled surgical trials can pose considerable risk for participants, they can also provide high-quality data about surgical efficacy. In a systematic review using strict definitions of "surgery" and "placebo," it was concluded that placebo control groups would be warranted in future randomized controlled trials. 37 However, only a minority of trials were methodologically appropriate for distinguishing placebo effects from the actual effects of surgery. Several stand out an early study compared internal mammary artery ligation and sham operation for angina pectoris and reported that patients experienced equal relief from the sham procedure as from ligation. 68 Another randomized placebo-controlled trial of percutaneous myocardial laser revascularization for patients with severe coronary disease found no benefit beyond a sham procedure for refractory angina. 69 Surprisingly, in a double-blind randomized crossover study of pacemaker implantation for obstructive hypertrophic cardiomyopathy, though there were better physiological outcomes for active pacing, placebo effects on objective and subjective parameters were documented for sham (inactive) pacemakers. 70 Then, in the landmark placebo-controlled clinical trial of arthroscopy for osteoarthritis of the knee, subjective and objective outcomes of surgery were found to be no better than those of a placebo procedure. 71 Double-blind controlled trials have also been tried in the context of neurosurgery for PD. 76 The authors found that although clinical effects did not appear to be broadly applicable, placebo interventions could be effective for specific conditions (eg, pain and nausea). For example, in trials with continuous outcomes (158) assessed by standardized mean difference (SMD or Cohen's d), statistically significant effects of placebo treatments were found for pain, nausea, asthma and phobia, but not for smoking, dementia, depression, obesity, hypertension, insomnia or anxiety. Meta-analyses showed larger effects of placebo interventions were associated with physical interventions (eg, sham acupuncture), smaller trials, trials with patient involvement or cooperation and trials that withheld information about possible placebo interventions. Over the past decade, studies in a number of disease conditions using OLP methods have begun to extend the results of previous research. In patients with irritable bowel syndrome, open administration of placebo, when delivered with positive suggestions about the placebo response, showed decreased symptoms of irritable bowel syndrome compared to the no-treatment group. 77 Similarly, a small pilot study compared OLP to no treatment among 20 nonpsychotic major depression patients, yet clinical improvement was relatively small and statistical power was low.
78
A randomized controlled trial compared OLP to no treatment among 25 patients with allergic rhinitis, the OLP arm showing greater symptoms improvement after 2 weeks of therapy. 79 Other studies have compared OLP to the standard treatment instead of no treatment. OLP was found to be at least as effective as standard care among patients with migraine and attention deficit hyperactive syndrome and even superior to nonsteroidal medications for patients with low back pain. [80] [81] [82] Finally, a recent randomized blinded controlled trial compared the use of OLP to the standard therapy for 74 cancer survivors with chronic fatigue. OLP participants reported a 29% improvement in fatigue severity and a 39% improvement in fatigue-disrupted quality of life compared to the standard of care. 83 In a systematic review of the five aforementioned OLP trials, a positive effect of OLP groups was found compared to no-treatment groups. 84 The authors noted several sources of heterogeneity in the small number of studies selected and that manipulation of the therapeutic encounter may have biased the experimental and/or control groups (viz. Hawthorne and John Henry effect, respectively), as in four out of five studies positive suggestion was juxtaposed with the OLP intervention.
| Pros and cons of open-label placebo
The use of OLP offers several advantages. First, the incremental effectiveness of OLP was reported in some studies to be higher than the often cited 30% effectiveness of traditional deceptive placebo in clinical trials. For instance, the placebo response in the irritable bowel syndrome trial (59%) was substantially higher than reported placebo responses of 30%-40% in other double-blind irritable bowel syndrome trials. 77, 85 It was hypothesized by the authors that while patients in double-blind trials understand they have only a 50% chance of receiving active treatment, in an OLP trial all the patients know they will receive the treatment of interest, which leads to stronger "placebogenic" responses. Second, OLP is inexpensive with lower adverse reactions, resulting in higher compliance compared to the standard of care. 82 Third, the use of placebo in clinical practice has been considered unethical since it facilitates therapeutic response through deception. OLP, on the other hand, is accompanied by informed consent and transparency, which seems to solve the ethical controversy of placebo use. 86 Moreover, the acceptance of OLP regimens by patients appears to be high, as 85% of surveyed patients felt it was acceptable for a physician to use a placebo. 87 Regardless of the advantages of OLP, the aforementioned trials pose some limitations. These include small sample size, heterogeneity of medical conditions studied, and lack of long-term follow-up to examine long-term effects of OLP. In addition, no comparison of OLP with deceptive placebo has ever been conducted. An important methodological challenge of OLP trials is the lack of blinded randomization. This phenomenon may increase participant awareness, which influences their perception of the therapeutic encounter and thus may alter their ability to detect treatment effects. 83 In addition, during the enrolment phase of OLP trials, patients are usually provided with a rationale explaining why OLP might be effective, which could enhance positive expectancy toward OLP treatment and increase its effectiveness. And yet, any treatment used in clinical practice is, or should be, accompanied by rational explanations.
| CLINICAL IMPLICATIONS
In several surveys conducted among physicians, it appears that placebo use is common in clinical practice worldwide. [88] [89] [90] In a meta-analysis of twenty-two surveys from twelve countries, the proportion of physicians that use pure placebos (inert interventions) varied between 17% and 80%. The proportion of nurses using pure placebos varied between 51% and 100%. The definitions of impure placebos (ineffective active interventions, eg, antibiotics for viral infections) were often unclear and uses varied widely. Furthermore, there appeared to be great heterogeneity of views and attitudes towards placebos among health care professionals and patients. In another survey of 1200 practising internists and rheumatologists in the United States, roughly half used placebo treatments, mainly vitamins and over the counter analgesics. 91 Of these physicians that used placebo treatments, most described placebo use to their patients as a "potentially beneficial medicine or treatment not typically used for their condition". Placebo use shows high acceptance rate among patients in general. In a survey of 853 US citizens, the majority (50%-84%) indicated that it is acceptable for doctors to recommend placebo treatments in different conditions. 92 Survey participants valued honesty and transparency by physicians regarding the use of placebos. Interestingly, over 80% of subjects stated that for a placebo treatment to be effective, deception is necessary and permissible. Still, other factors are also likely to play a role, including from patients perspectives regarding placebo, for example, biopsychosocial forces arising from contact with a health care providers and lowered patient anxiety due to a positive expectation of recovery due to placebo treatment. 93 
| CONCLUSION
The approach to placebo treatment has shifted substantially in the last decade. In contrast to deceptive administration and the focus on required measurements in clinical trials, placebo treatments have increasingly been recognized as a means of creating significant therapeutic response. Several open-label placebo trials conducted recently have contributed to the notion that placebos do not need to be used with deception in order to produce meaningful effects. Future studies should be of larger scale and longer duration, using assessor-blinded randomization with open-label placebos to further examine the role of placebo interventions in clinical practice, opening up new opportunities for future mechanistic research.
